<DOC>
	<DOCNO>NCT01068301</DOCNO>
	<brief_summary>Patients refractory hematologic malignancy , include develop recurrent disease allogeneic hematopoietic stem cell transplantation ( HSCT ) dismal prognosis . Historically , regimen-related mortality disease recurrence significant cause treatment failure heavily pre-treated patient population . Novel therapeutic agent target molecular signal mechanisms increase sensitivity leukemic cell apoptosis may clearly play role set . This study hypothesize interrupt SDF-1/CXCR4 axis use selective CXCR4 antagonist plerixafor may useful leukemic stem cell mobilize agent patient refractory standard dose chemotherapy relapse allogeneic transplant . This hypothesis base dependence leukemia cell MSCs survival signal describe preclinical data suggest increase efficacy antileukemia agent leukemia cell separate MSCs . In present trial , study proposes add plerixafor enhance condition regimen cytotoxicity . At time goal determine maximum tolerate dose ( MTD ) plerixafor process dose limit toxicity ( DLT ) evaluation . Pharmacokinetic study conduct . Additional study quantify content leukemia cell key regulatory effector T cell population bone marrow blood exposure medication . If observe outcomes trial promising , could serve platform study use plerixafor complimentary agent condition well chemotherapeutic regimen patient relapse refractory hematologic malignancy .</brief_summary>
	<brief_title>A Pediatric Study Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>This study determine follow objective : 1 . To determine dose-limiting toxicity ( DLT ) maximum tolerate dose ( MTD ) plerixafor combination fludarabine , thiotepa , melphalan condition regimen child young adult undergoing second allogeneic stem cell transplant ( SCT ) procedure . 2 . The study determine secondary objective : - To describe pharmacokinetic property plerixafor study population - To estimate cumulative incidence relapse overall survival study participant one year second transplant procedure 3 . Other exploratory objective include : - To study correlation pharmacokinetic property plerixafor key regulatory effector T cell population blood exposure plerixafor . - To evaluate content leukemia cell bone marrow blood exposure plerixafor - To evaluate key regulatory effector T cell population bone marrow blood exposure plerixafor</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Age le equal 21 year old . One follow hematologic malignancy relapse prior allogeneic hematopoietic stem cell transplantation : Acute lymphoblastic leukemia ( ALL ) Acute myeloid leukemia ( AML ) Myelodysplastic syndrome ( MDS ) Chronic myeloid leukemia ( CML ) Juvenile myelomonocytic leukemia ( JMML ) NonHodgkin 's lymphoma ( NHL ) evidence bone marrow disease Has suitable human leukocyte antigen ( HLA ) match family member unrelated donor available stem cell donation . A `` matched '' donor define match 5/6 6/6 HLA locus . Does active central nervous system ( CNS ) malignancy ( history CNS disease allow ) . No prior neuromuscular dysfunction prior grade IIV neuromuscular dysfunction subside &gt; 4 week prior enrollment . Cardiac shorten fraction great equal 25 % . Creatinine clearance great equal 50 ml/min/1.73 m2 Forced vital capacity ( FVC ) great equal 40 % predict value pulse oximetry great equal 92 % room air . Karnofsky Lansky ( agedependent ) performance score great equal 50 . Off treatment acute chronic graftversushost disease ( GVHD ) least 7 day prior initiation conditioning . Bilirubin le equal 3 time upper limit normal age . Alanine aminotransferase ( ALT ) less equal 3.0 time upper limit normal age . White blood cell count le 50,000/mm3 Not pregnant confirm negative serum urine pregnancy test within 14 day prior enrollment . Not lactate . All patient childbearing potential must agree use effective birth control method Pregnant lactating female exclude participation short longterm effect preparative agent infusion fetus nursing child breast milk entirely known time .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Allogeneic Stem Cell transplantation</keyword>
	<keyword>Plerixafor</keyword>
	<keyword>Acute Lymphoblastic leukemia</keyword>
	<keyword>Acute Myeloid leukemia</keyword>
	<keyword>Chronic Myeloid leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Other Leukemia</keyword>
</DOC>